LeMaitre (LMAT)
Makes vascular grafts, patches, and shunts while providing human-tissue cryopreservation services.
Something off on this page? Send us feedback.
Sells vascular grafts, patches, shunts, catheters, and related surgical devices, alongside human-tissue processing and cryopreservation services. A focused direct sales force generates most revenue, with all product lines and services reported in one operating segment.
Develops, manufactures, and markets devices and implants used mainly in vascular surgery, while processing and cryopreserving human vascular and cardiac tissue. Core lines include biologic and synthetic vascular and dialysis grafts, vascular and cardiac patches, carotid shunts, valvulotomes, embolectomy and occlusion catheters, anastomotic clips, and radiopaque marking tape.
Sells primarily to hospitals through a focused direct sales force, with distributors covering other territories. Products reach the United States, Europe, Canada, and Asia Pacific, and the commercial model uses the same specialist channel to add complementary products and convert selected distributor markets to direct sales.
Operates as one segment. Demand follows vascular, dialysis, and cardiovascular procedures, while manufacturing and tissue processing remain subject to medical-device and human-tissue regulation across the markets served.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 6, 2026 | Barrington | Target | Target: $120 | Target: $95 |
| May 6, 2026 | Lake Street | Target | Target: $110 | Target: $135 |
| May 6, 2026 | Barrington | Target | Target: — | Target: $120 |
| Nov 10, 2025 | Cantor Fitzgerald | Target | Target: $96 | Target: $95 |
| Nov 5, 2025 | Roth Capital | Target | Target: — | Target: $108 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $376.2M · Total debt $190.3M · Total assets $640.5M · Shareholders' equity $420.3M
- Revenue
- $70.4M
- Operating income
- $20.4M
- Net income
- $17.1M
HistoryDividendAnnual yield
| Institutions | ≈ 101.11% | 23.12M shares | |
|---|---|---|---|
| 329 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 6.91% | 1.58M shares | |
| 10 holders · as of Sep 3, 2026 | |||
| Adds to | 108.02% | ||
22.87M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 108.02%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 14.31% | 3.27M | as of Jun 30, 2026 |
George W. LeMaitreInsiderdirector, officer: Chairman and CEO | 6.40% | 1.46M | filed Jun 5, 2026 |
Conestoga Capital Advisors, LLCInstitution | 5.98% | 1.37M | as of Jun 30, 2026 |
First Trust Portfolios L.P.Institution | 5.14% | 1.18M | filed Jul 27, 2026 |
First Trust Advisors LPInstitution | 4.78% | 1.09M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 7, 2026 | Lawrence J. Jasinski | director | −3,943 | $110.00 |
| May 7, 2026 | Bridget A. Ross | director | −5,044 | $111.10 |
| May 8, 2026 | Trent G. Kamke | officer: Senior V. P., Operations | −2,928 | $107.00 |
| May 8, 2026 | George W. LeMaitre | director, officer: Chairman and CEO | −27,881 | $108.69 |
| May 7, 2026 | George W. LeMaitre | director, officer: Chairman and CEO | −18,600 | $107.64 |
- BD
Broad peripheral vascular overlap through Bard devices
- Artivion
Focused tissue and graft rival in cardiac and vascular surgery
- Abbott
Vascular intervention giant pressuring open-surgery niches
- Edwards Lifesciences
Cardiac surgery overlap around valves and repair products
- Humacyte
Bioengineered vascular conduit challenger
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| LeMaitre | $80.98 | 0.00% | $1.81B | 27.8 | 26.5 | 6.9 | +9.6% |
| BD | $183.00 | −0.03% | $49.79B | 54.4 | 13.8 | 2.4 | −9.6% |
| Artivion | $24.62 | +1.99% | $1.15B | — | 73.1 | 2.4 | +11.3% |
| Abbott | $103.35 | −0.36% | $178.18B | 33.1 | 17.9 | 3.8 | +13.0% |
| Edwards Lifesciences | $88.78 | −0.02% | $50.87B | 50.8 | 28.3 | 7.8 | +13.6% |
| Humacyte | $0.5900 | +1.18% | $99.1M | — | — | 46.7 | +34.9% |
| Median | 50.8 | 23.1 | 3.8 | +13.0% |